BamSEC and AlphaSense Join Forces
Learn More

BioMarin Pharmaceutical Inc.

NASDAQ: BMRN    
Share price (12/23/24): $66.27    
Market cap (12/23/24): $12.6 billion
Search in Documents
Key Exhibits
External Links

Indentures Filter

EX-4.1
from 8-K 119 pages Indenture Dated as of May 14, 2020 Between Biomarin Pharmaceutical Inc. and U.S. Bank National Association, as Trustee 1.25% Convertible Senior Subordinated Notes Due 2027
12/34/56
EX-4.6
from 10-K 3 pages Description of Capital Stock
12/34/56
EX-4.2
from 8-K 84 pages First Supplemental Indenture Dated as of August 11, 2017 to Indenture Dated as of August 11, 2017 Between Biomarin Pharmaceutical Inc. and Wilmington Trust, National Association, as Trustee
12/34/56
EX-4.1
from 8-K 43 pages Biomarin Pharmaceutical Inc., Issuer and Wilmington Trust, National Assocation, Trustee Indenture Dated as of August 11, 2017 Debt Securities
12/34/56
EX-4.4
from S-3ASR 35 pages Biomarin Pharmaceutical Inc., Issuer and [Trustee], Trustee Indenture Dated as of [●], 20 Debt Securities
12/34/56
EX-4.3
from 8-K 82 pages Second Supplemental Indenture Dated as of October 15, 2013 to Indenture Dated as of October 15, 2013 Between Biomarin Pharmaceutical Inc. and Wilmington Trust, National Association, as Trustee
12/34/56
EX-4.2
from 8-K 82 pages First Supplemental Indenture Dated as of October 15, 2013 to Indenture Dated as of October 15, 2013 Between Biomarin Pharmaceutical Inc. and Wilmington Trust, National Association, as Trustee
12/34/56
EX-4.1
from 8-K 51 pages Biomarin Pharmaceutical Inc. Indenture Dated as of October 15, 2013 Wilmington Trust, National Association, a National Banking Association, as Trustee
12/34/56
EX-4.1
from S-3ASR 51 pages Biomarin Pharmaceutical Inc. Indenture Dated as of October , 2013 Wilmington Trust, National Association, a National Banking Association, as Trustee
12/34/56
EX-4.5
from S-8 27 pages Biomarin Pharmaceutical Inc. 2006 Share Incentive Plan (As Amended and Restated on March 22, 2010, and as Amended on March 28, 2013) Plan Document
12/34/56
EX-4.2
from 8-A12G/A 2 pages Amendment No. 1 to Amended and Restated Rights Agreement
12/34/56
EX-4.1
from 10-K 65 pages Biomarin Pharmaceutical Inc. a Delaware Corporation and Mellon Investor Services LLC a New Jersey Limited Liability Company as Rights Agent Amended and Restated Rights Agreement Dated as of February 27, 2009
12/34/56
EX-4.2
from 8-K 15 pages Biomarin Pharmaceutical Inc. 1.875% Senior Subordinated Convertible Notes Due 2017 No. A1 Cusip: 09061g Ad3
12/34/56
EX-4.1
from 8-K 77 pages Second Supplemental Indenture Dated as of April 23, 2007 Between Biomarin Pharmaceutical Inc. and Wilmington Trust Company Trustee
12/34/56
EX-4.3
from 8-K 14 pages Biomarin Pharmaceutical Inc. 2.50% Senior Subordinated Convertible Notes Due 2013 No. A1 Cusip: 09061g Ac 5
12/34/56
EX-4.2
from 8-K 72 pages First Supplemental Indenture Dated as of March 29, 2006 Between Biomarin Pharmaceutical Inc. and Wilmington Trust Company Trustee
12/34/56
EX-4.1
from 8-K 49 pages Biomarin Pharmaceutical Inc. Indenture Dated as of March 29, 2006 Wilmington Trust Company, a Delaware Banking Corporation, as Trustee
12/34/56
EX-4.1
from S-3ASR 49 pages Biomarin Pharmaceutical Inc. Indenture Dated as of March ___, 2006 Wilmington Trust Company, a Delaware Corporation, as Trustee
12/34/56
EX-4.3
from 10-Q 28 pages Registration Rights Agreement
12/34/56
EX-4.2
from 10-Q 16 pages 3.50% Convertible Subordinated Note Due 2008 Cusip No. 09061g Aa 9
12/34/56